Markets:

Overview

News

Currencies

International

Treasuries

Blueprint Medicines Corporation - Common Stock (NQ:BPMC)

129.46 UNCHANGED

Last Price Updated: 4:00 PM EDT, Jul 17, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Blueprint Medicines Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Blueprint Stock Dives On The FDA's Tricky New Requirement For Its Leading Drug ↗

June 09, 2022

The FDA had a suggestion for Blueprint's midstage systemic mastocytosis test.

Via Investor's Business Daily

Bristol Myers Snaps Up Turning Point For $4.1 Billion In Cash — Is The Biotech Bear Dead? ↗

June 03, 2022

Bristol Myers is moving deeper into the targeted oncology space.

Via Investor's Business Daily

Benzinga's Top Ratings Upgrades, Downgrades For June 1, 2022 ↗

June 01, 2022

Upgrades

Via Benzinga

10 Biggest Price Target Changes For Wednesday ↗

June 01, 2022

Keybanc cut Ambarella, Inc. (NASDAQ: AMBA) price target from $160 to $120. Ambarella shares fell 5% to $81.00 in pre-market trading.

Via Benzinga

Blueprint Medicines: Q1 Earnings Insights ↗

May 03, 2022

Blueprint Medicines (NASDAQ:BPMC) reported its Q1 earnings results on Tuesday, May 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Earnings Scheduled For February 16, 2022 ↗

February 16, 2022

Companies Reporting Before The Bell • Wix.com (NASDAQ:WIX) is projected to report quarterly loss at $0.38 per share on revenue of $331.16 million.

Via Benzinga

EMA's Advisory Committee Recommends Approval Of Blueprint Medicines' Avapritinib In Blood Disorder ↗

January 28, 2022

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has

Via Benzinga

What 3 Analyst Ratings Have To Say About Blueprint Medicines ↗

May 19, 2022

Blueprint Medicines (NASDAQ:BPMC) has observed the following analyst ratings within the last quarter:

Via Benzinga

The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs ↗

May 03, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

Earnings Preview: Blueprint Medicines ↗

May 02, 2022

Blueprint Medicines (NASDAQ:BPMC) is set to give its latest quarterly earnings report on Tuesday, 2022-05-03. Here's what investors need to know before the announcement. Analysts estimate that...

Via Benzinga

Blueprint Medicines Q1 2022 Earnings Conference Call On May 3, 2022 At 08:30 AM ET ↗

April 27, 2022

Blueprint Medicines (NASDAQ:BPMC) will host a conference call at 08:30 AM ET on May 3, 2022, to discuss Q1 2022 earnings results.

Via Benzinga

Analyst Ratings For Blueprint Medicines ↗

January 25, 2022

Analysts have provided the following ratings for Blueprint Medicines (NASDAQ:BP...

Via Benzinga

Where Blueprint Medicines Stands With Analysts ↗

April 13, 2022

Over the past 3 months, 6 analysts have published their opinion on Blueprint Medicines (NASDAQ:BPMC) stock. These analysts are typically employed by large Wall Street banks and tasked with...

Via Benzinga

After Encouraging Data, Blueprint Medicines Plans Combination Cohort In Tagrisso Resistant Lung Cancer ↗

April 11, 2022

Blueprint Medicines Corp (NASDAQ: BPMC)

Via Benzinga

Wednesdays With Wedbush: 3 Smid-Cap Biotech Stock Picks ↗

March 09, 2022

Since the coronavirus pandemic began in early 2020, the FDA's plate has been full with reviews of COVID-19 vaccines and treatments. That has put the approval of many...

Via Benzinga

What 5 Analyst Ratings Have To Say About Blueprint Medicines ↗

March 01, 2022

Over the past 3 months, 5 analysts have published their opinion on Blueprint Medicines (NASDAQ:BPMC) stock. These analysts are typically employed by large Wall Street banks and...

Via Benzinga

Blueprint Medicines, Proteovant Collaboration For Protein Degrader Therapies ↗

February 28, 2022

Blueprint Medicines Corporation (NASDAQ: BPMC) and Proteovant Therapeutics have entered a strategic collaboration for targeted protein degrader therapies....

Via Benzinga

Stocks That Hit 52-Week Lows On Friday ↗

February 25, 2022

During Friday's trading, 54 companies set new 52-week lows. Things to Consider About Today's 52-Week Lows: The largest company by market cap to hit a new 52-week...

Via Benzinga

Stocks That Hit 52-Week Lows On Tuesday ↗

March 01, 2022

During Tuesday's trading, 98 companies set new 52-week lows. Intriguing Points From Today's 52-Week Lows And Highs: JPMorgan Chase (NYSE:JPM) was the...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2022 ↗

March 01, 2022

Upgrades Stifel upgraded the previous rating for Revolution Medicines Inc (NASDAQ:RVMD) from Hold to Buy. For the fourth quarter, Revolution Medicines had an EPS of $0.71,...

Via Benzinga

Where Blueprint Medicines Stands With Analysts ↗

February 17, 2022

Over the past 3 months, 5 analysts have published their opinion on Blueprint Medicines (NASDAQ:BPMC) stock. These analysts are typically employed by large Wall Street banks and...

Via Benzinga

The Daily Biotech Pulse: Avenue Tumbles On Negative Adcom Verdict, Moderna's Expanded Deal With Rovi, Gilead Takes Equity Stake In Hookipa ↗

February 16, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Hookipa Gets $15M Upfront Payment And Equity Investment From Gilead Following...

Via Benzinga

Stocks That Hit 52-Week Lows On Monday ↗

February 28, 2022

On Monday morning, 66 companies achieved new lows for the year. Noteable 52-Week Lows: Gilead Sciences (NASDAQ:GILD) was the largest firm on a market cap basis to set a...

Via Benzinga

Earnings Preview: Blueprint Medicines ↗

February 15, 2022

Blueprint Medicines (NASDAQ:BPMC) is set to give its latest quarterly earnings report on Wednesday, 2022-02-16. Here's what investors need to know before the announcement. Analysts estimate that...

Via Benzinga

The Week Ahead In Biotech (Feb. 13-19): Agios FDA Meeting, Avenue Adcom, Earnings And More ↗

February 13, 2022

Biotech stocks moved back and forth amid some volatility before finishing the week ending Feb. 11 modestly lower, reversing the gains from the previous week. Earnings news...

Via Benzinga

10 Biggest Price Target Changes For Tuesday ↗

January 25, 2022

Needham cut Medtronic plc (NYSE:MDT) price target f...

Via Benzinga

Biotech Bloodbath Continues Despite Gene-Editing Deals For Pfizer, Bayer ↗

January 10, 2022

Pfizer and Bayer inked deals with several companies in gene-editing.

Via Investor's Business Daily

50 Biggest Movers From Yesterday ↗

January 06, 2022

Gainers Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) shares surged 63.7% to settle at $2.21 on Wednesday after the company announced that in preclinical studies its lead...

Via Benzinga

34 Stocks Moving In Wednesday's Mid-Day Session ↗

January 05, 2022

Gainers Mainz Biomed B.V. (NASDAQ: MYNZ) shares climbed 49.7% to $15.45 after the company announced it acquired exclusive rights to novel mRNA biomarkers. Data Storage...

Via Benzinga

Blueprint Medicines Expands Precision Therapy With Lengo Therapeutics Acquisition ↗

November 29, 2021

Blueprint Medicines Corporation (NASDAQ: BPMC) has agreed to acquire Lengo Therapeutics, a privately held precision oncology company. The deal consideration...

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Blueprint Medicines Corporation - Common Stock (NQ:BPMC)

Headline News about Blueprint Medicines Corporation - Common Stock

Starting at $3.75/week.

Subscribe Today